“In Vitro Diagnostics (IVD) market set to grow to $91bn by 2024” says new Visiongain report

14 May 2019
Pharma

Visiongain has launched a new pharma report Medical Devices Leader Series: Top In Vitro Diagnostics (IVD) Companies 2019-2029: Danaher Corporation, Abbott Laboratories, Bio-Rad Laboratories, Roche, Siemens AG, Sysmex, Other Companies.

The global in vitro diagnostics (IVD) market is estimated to have reached $69.2bn in 2018. In 2018, Visiongain notes that Big Pharma companies, namely Roche, Danaher and Siemens dominated the sector accounting for 42.4% of the global IVD market with combined revenue of $29.3bn.

The lead analyst of the report commented "In recent years, the IVD market has experienced increased consolidation among industry participants, with significant merger and acquisition (M&A) activity, especially among larger companies as they diversify and manoeuvre for stronger positions. This has been done primarily in response to increased competition to maintain or increase market share, and to solidify a company’s position in the market. Small innovative companies are providing new technologies which feed into the development of products by leading players. Such companies represent potential acquisition targets for corporations seeking opportunities."

Leading companies featured in the report include Abbott Laboratories, Becton, Dickinson and Company (BD), Bio-Rad Laboratories, Inc., Danaher Corporation, Laboratory Corporation of America (LabCorp), QIAGEN, Roche, Siemens AG, Sysmex Corporation, Thermo Fisher Scientific and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Influenza Vaccines Market Set to Grow to $4.9bn by 2024” says new Visiongain report

The global vaccines market is one that is driven by innovation. This is vital for maintaining the rich pipeline of vaccines seen in the human vaccines market.

05 July 2019

Read

“Pharmaceutical Wholesale & Distribution Organizations 2019 is estimated to reach $1.4bn in 2024” says Visiongain report

Opportunities in the market stem from the increasing use of specialist and generic drugs, which have higher profit margins; global expansion into the emerging markets; vertical integration of wholesalers; and the increasing use of pharmaceuticals.

28 June 2019

Read

“Global Vaccines Sales market set to grow to $75bn by 2024” says new Visiongain report

Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.

25 June 2019

Read

“Global Inflammatory Bowel Diseases (IBD) Drug Market is estimated to reach $8.6bn by 2024” says new Visiongain report

Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.

21 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever